Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of HLX43 (anti-PD-L1 ADC) in Advanced Pancreatic Cancer
ChiCTR2600122046Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HLX43 in pancreatic adenocarcinoma (PDAC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Objective response rate, Disease control rate and 3 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
HLX43
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2600122046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122046.